Navigation Links
'Liquid biopsy' offers new way to track lung cancer
Date:6/3/2014

Scientists have shown how a lung cancer patient's blood sample could be used to monitor and predict their response to treatment paving the way for personalised medicine for the disease.

The recent study, published in the journal Nature Medicine, also offers a method to test new therapies in the lab and to better understand how tumours become resistant to drugs.

Small cell lung cancer (SCLC) is an aggressive disease with poor survival and new treatments are desperately needed. In many cases the tumour is inoperable and biopsies are difficult to obtain, giving scientists few samples with which to study the disease.

Now research carried out at Cancer Research UK's Manchester Institute, based at The University of Manchester part of the Manchester Cancer Research Centre has looked at the potential of using circulating tumour cells (CTCs) cells that have broken off from the tumour and are circulating in the blood to investigate a patient's disease in a minimally invasive manner.

The researchers, working closely with lung specialist and Medical Oncologist Dr Fiona Blackhall at The Christie NHS Foundation Trust, found that patients with SCLC had many more CTCs in a small sample of their blood than patients with other types of cancer. Importantly, the number of CTCs for each patient was related to their survival patients with fewer CTCs in their blood lived longer.

Professor Caroline Dive, who led the study, said: "Access to sufficient tumour tissue is a major barrier to us fully understanding the biology of SCLC. This liquid biopsy is straightforward and not invasive so can be easily repeated and will allow us to study the genetics of each lung cancer patient's individual tumour. It also means that we may have a feasible way of monitoring patient response to therapy, hopefully allowing us to personalise and tailor individual treatment plans to each patient."

In addition, the team were able to use these CTCs to grow tumour models in mice, which they termed CTC-derived explants (CDXs). When they treated these mice with the same chemotherapy drugs as the SCLC patients they showed that the CDXs responded in the same way as each donor patient.

"We can use these models to help us understand why so many SCLC patients acquire resistance to chemotherapy and to search for and test potential new targeted treatments," added Professor Dive.


'/>"/>

Contact: Alison Barbuti
alison.barbuti@manchester.ac.uk
44-016-127-58383
University of Manchester
Source:Eurekalert

Related medicine news :

1. Sperm Collide Along Liquid Maze on Way to Fertilize Egg
2. Social Smoking Announces New Product Line of E-Cig Liquids
3. True-Dose to Exhibit Liquid Pet Supplements at the Cardinal Health Retail Business Conference in Orlando, FL on July 11-14
4. Liquidation Channel Announces its Fourth of July Celebrations Featuring Diamond Smackdown
5. New Prep for Colon Screen Uses Four Pills, Not Liquid Laxative
6. Scientists use sound waves to levitate liquids, improve pharmaceuticals
7. Results from study of Mead Johnsons Enfamil® Human Milk Fortifier Acidified Liquid published in Pediatrics
8. Aldrich Materials Science discovers liquid-free preparation of metal organic frameworks
9. Complete H2O Minerals Has Developed a Product for Seniors Using the Benefits of Liquid Vitamins and Minerals
10. Complete H2O Minerals Has Developed a Product for Women Using the Benefits of Liquid Vitamins and Minerals
11. Liquid Facelift Hawaii Expands Slate of Non-Surgical Procedures to Combat Aging
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... Boca Raton, Florida (PRWEB) , ... April 24, 2017 , ... ... natural chai teas, announced its products are now available for purchase on RevNutrition.com, a ... ancient form of tea first produced and popularized in ancient India and Siam. It ...
(Date:4/24/2017)... , ... April 24, 2017 , ... ... healthcare compliance and credentialing solutions, today announced that Kyle Allain has joined the ... Cactus Provider Management sales and operations, including provider, payor and managed care solutions. ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... to be diagnosed globally; approximately 25,000 of them will be malignant.(1) As research ... of this type of healthcare model in the diagnosis and treatment of brain ...
(Date:4/24/2017)... IL (PRWEB) , ... April 24, 2017 , ... Rod ... the Senior Housing News website. , Rod has been at the forefront of Gardant ... company’s culture. As CEO, Rod has overseen the opening of more than 40 new ...
(Date:4/24/2017)... ... April 24, 2017 , ... As a former supermodel known for ... The good news for single women is that she put all the words in ... April 25th. Joan's insight, personal experiences and sparkling sense of humor have inspired her ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... April 20, 2017  Cogentix Medical, Inc. (NASDAQ: ... providing the Urology, Uro/Gyn and Gynecology markets with ... Keswani has joined the Company as Senior Vice ... created position, Mr. Keswani will report directly to ... "Our organization is delighted that Ash has ...
(Date:4/20/2017)... 20, 2017  RXi Pharmaceuticals Corporation (NASDAQ: RXII), ... address significant unmet medical needs, today announced that ... consumer product development program, based on its proprietary ... Investigative Dermatology (SID) 76 th Annual Meeting.  ... the sciences relevant to skin health and disease ...
(Date:4/20/2017)... -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today ... C virus (HCV) infected patients with genotype 1, ... (Child-Pugh A) achieved sustained virologic response at 12 ... pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These high SVR ... of G/P treatment without ribavirin. Patients with specific ...
Breaking Medicine Technology: